BIOCIENCIAS: Bª Y CLÍNICA DEL CÁNCER Y MEDIC. TRASLACIONAL
Escuela de doctorado
Alfonso Jesús
Domínguez-Gil Hurlé
Profesor Emérito Honorífico
Publicaciones en las que colabora con Alfonso Jesús Domínguez-Gil Hurlé (47)
2014
-
Population pharmacokinetic/pharmacogenetic model of lopinavir/ritonavir in HIV-infected patients
Personalized Medicine, Vol. 11, Núm. 7, pp. 693-704
2013
-
Nuevas estrategias en la optimización posológica de lopinavir/ritonavir en pacientes infectados por el virus de la inmunodeficiencia humana
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 31, Núm. 1, pp. 36-43
2011
-
Population pharmacokinetic/pharmacogenetic model for optimization of Efavirenz therapy in caucasian HIV-infected patients
Antimicrobial Agents and Chemotherapy, Vol. 55, Núm. 11, pp. 5314-5324
-
Terapia personalizada en la infección por el VIH: Aplicación de criterios farmacogenéticos
Anales de la Real Academia de Medicina y Cirugía de Valladolid, Núm. 48, pp. 75-99
2010
-
Consensus document on the use of biosimilar granulocyte-colony stimulating factor for the correction of neutropenia associated in cancer patients
Farmacia Hospitalaria, Vol. 34, Núm. SUPPL. 1, pp. 45-50
2009
-
Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients
Antimicrobial Agents and Chemotherapy, Vol. 53, Núm. 7, pp. 2791-2798
-
Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokineticpharmacodynamic analysis
Clinical Pharmacokinetics, Vol. 48, Núm. 4, pp. 273-280
2008
-
Clozapine may partially compensate for task-related brain perfusion abnormalities in risperidone-resistant schizophrenia patients
Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 32, Núm. 4, pp. 948-954
-
Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in german and spanish patients with epilepsy
Therapeutic Drug Monitoring, Vol. 30, Núm. 4, pp. 483-489
2006
-
Therapeutic drug monitoring of itraconazole and the relevance of pharmacokinetic interactions
Clinical Microbiology and Infection, Vol. 12, Núm. SUPPL. 7, pp. 97-106
2005
-
Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies
Antimicrobial Agents and Chemotherapy, Vol. 49, Núm. 12, pp. 4934-4941
2004
-
Iniciación de un programa de monitorización de lamotrigina en pacientes epilépticos
Atencion Farmaceutica, Vol. 6, Núm. 2, pp. 97-101
2001
-
Farmacocinética de poblaciones: Una aproximación a la optimización del tratamiento con antimicrobianos
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 19, Núm. 5, pp. 219-228
1999
-
Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data
Biopharmaceutics and Drug Disposition, Vol. 20, Núm. 5, pp. 233-240
-
Population pharmacokinetics of amikacin in patients with haematological malignancies
Journal of Antimicrobial Chemotherapy, Vol. 44, Núm. 2, pp. 235-242
-
Valproate population pharmacokinetics in children
Journal of Clinical Pharmacy and Therapeutics, Vol. 24, Núm. 1, pp. 73-80
1997
-
Carbamazepine population pharmacokinetics in children: Mixed-effect models
Therapeutic Drug Monitoring, Vol. 19, Núm. 2, pp. 132-139
-
Population pharmacokinetics of caffeine in premature neonates
European Journal of Clinical Pharmacology, Vol. 52, Núm. 3, pp. 211-217
1996
-
Bayesian forecasting in paediatric populations
Clinical Pharmacokinetics
-
Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies
Clinical Pharmacology and Therapeutics, Vol. 60, Núm. 3, pp. 332-340